Biology of Blood and Marrow TransplantationThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

669 records returned

Table of ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 6, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

Officers and Directors of ASBMTEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 6, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 6, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

MastheadEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 6, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

ASBMT NewsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Allogeneic stem cell transplants for myelodysplastic syndrome (MDS) would be consistently eligible for Medicare and Medicaid reimbursement if the federal government accepts a formal request that has been submitted by ASBMT and the National Marrow Donor Program (NMDP), together with 10 other organizations. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 6, 2009 Category: Hematology Tags: ASBMT News Source Type: journals

Blood Stem Cell Transplantation in Older PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This report recommends research priorities that can help close the gaps in our understanding of aging as it relates to HSCT and cancer. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 6, 2009 Category: Hematology Authors: William J. Murphy, Andrew S. Artz, Richard E. Champlin, John Koreth, Dan L. Longo Tags: ASBMT Committee Report Source Type: journals

Table of ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 13, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

Officers and Directors of ASBMTEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 13, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 13, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

MastheadEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 13, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

Minor ABO-Mismatches are Risk Factors for Acute Graft-versus-Host Disease in Hematopoietic Stem Cell Transplant PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We investigated the impact of ABO and Rhesus (Rh) blood group matching on the outcome of hematopoietic stem cell transplantation (HSCT) of 154 patients matched at 10/10 HLA loci with unrelated donors. ABO and Rh, as potential risk factors, were modeled with the clinical outcome—acute and chronic graft-versus-host disease (aGVHD, cGVHD), relapse, treatment-related mortality (TRM), and overall survival (OS)—by simple, multiple, and competing risk analyses. We found that minor ABO-mismatches represent a significant risk factor for aGVHD (II-IV) with an estimated risk increase of almost 3-fold (hazard ratio [HR]=2.92, 95% ...
Source: Biology of Blood and Marrow Transplantation - October 13, 2009 Category: Hematology Authors: Katarina Ludajic, Yesilda Balavarca, Heike Bickeböller, Agathe Rosenmayr, Gottfried F. Fischer, Ingrid Faé, Peter Kalhs, David Pohlreich, Michal Kouba, Marie Dobrovolna, Hildegard T. Greinix Tags: Clinical Research Source Type: journals

2009 Research PrioritiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The American Society for Blood and Marrow Transplantation has reviewed recent advances and problems in hematopoietic cell transplantation (HCT), and has identified priorities in several areas of basic and clinical research: (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 30, 2009 Category: Hematology Tags: ASBMT Committee Report Source Type: journals

Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The proteasome and its associated ubiquitin protein modification system have proved to be an important therapeutic target in the treatment of multiple myeloma and other cancers. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on nonneoplastic immune cells. This indicates that proteasome inhibition, through the use of agents like bortezomib, could be used therapeutically to modulate immune responses. In this review we explore the emerging data, both preclinical and clinical, highlighting the importance of proteasome targeting of immunologic responses, primarily in the context of all...
Source: Biology of Blood and Marrow Transplantation - September 25, 2009 Category: Hematology Authors: John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak Tags: Review Source Type: journals

Impending Challenges in the Hematopoietic Stem Cell Transplantation Physician WorkforceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
With increasing use of high dose chemotherapy with autologous and allogeneic transplants the need for the transplant physician workforce requires reassessment. The types of transplants and patients are also shifting toward transplants being done in patients with more comorbidities and more commonly these types of patients require more work effort per patient from the transplant physician. Additionally, HSCT survivors often require ongoing care at the transplant center due to the inability of the primary care workforce or the hematology/oncology workforce to absorb caring for post complex post transplant patients. The adult...
Source: Biology of Blood and Marrow Transplantation - September 24, 2009 Category: Hematology Authors: James L. Gajewski, C. Frederick LeMaistre, Samuel M. Silver, Michael C. Lill, George B. Selby, Mary M. Horowitz, J. Douglas Rizzo, Helen E. Heslop, Claudio Anasetti, Richard T. Maziarz Tags: Commentary Source Type: journals

Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Although allogeneic hematopoietic progenitor cell transplant (HPCT) is curative therapy for many disorders, it is associated with significant morbidity and mortality, which can be related to graft-versus-host disease (GVHD) and the immunosuppressive measures required for its prevention and/or treatment. Whether the immunosuppression is pharmacologic or secondary to graft manipulation, the graft recipient is left at increased risk of the threatening opportunistic infection. Refractory viral diseases in the immunocompromised host have been treated by infusion of virus-specific lymphotyces and by unmanipulated donor lymphocyt...
Source: Biology of Blood and Marrow Transplantation - September 23, 2009 Category: Hematology Authors: Joanne Filicko-O'Hara, Dolores Grosso, Phyllis R. Flomenberg, Thea M. Friedman, Janet Brunner, William Drobyski, Andres Ferber, Irina Kakhniashvili, Carolyn Keever-Taylor, Bijoyesh Mookerjee, Julie-An Talano, John I. Wagner, Robert Korngold, Neal Flomenbe Tags: Clinical Research Source Type: journals

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete Remission: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Total body irradiation (TBI)-based conditioning regimens for pediatric patients with acute myelogenous leukemia (AML) beyond first complete remission (CR1) are controversial. Because the long-term morbidity of busulfan (Bu)-based regimens appears to be lower, determining efficacy is critical. We retrospectively evaluated 151 pediatric patients with AML beyond CR1, comparing outcomes in 90 patients who received a TBI-based conditioning regimen and 61 patients who received a Bu-based conditioning regimen. There were no differences between the 2 groups with respect to age, sex, duration of CR1, time from most recent remission...
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: India Y. Sisler, Elizabeth Koehler, Tatsuki Koyama, Jennifer A. Domm, Robin Ryan, John E. Levine, Michael A. Pulsipher, Paul R. Haut, Kirk R. Schultz, Douglas S. Taylor, Haydar A. Frangoul Tags: Clinical Research Source Type: journals

Tacrolimus/Methotrexate versus Cyclosporine/Methotrexate as Graft-versus-Host Disease Prophylaxis in Patients with Severe Aplastic Anemia Who Received Bone Marrow Transplantation from Unrelated Donors: Results of Matched Pair AnalysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tacrolimus (FK) and cyclosporine (CsA) have been shown to be effective in the prophylaxis of graft-versus-host disease (GVHD). However, no comparative studies have yet been conducted to examine the efficacy of FK/methotrexate (MTX) and CsA/MTX in patients with severe aplastic anemia (SAA) given unrelated donor bone marrow transplantation (U-BMT). We used matched-pair analysis to compare FK/MTX with CsA/MTX in patients with SAA who received U-BMT through the Japan Marrow Donor Program. Forty-seven pairs could be matched exactly for recipient age and conditioning regimens. Forty-five patients achieved engraftment in the FK g...
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: Hiroshi Yagasaki, Seiji Kojima, Hiromasa Yabe, Koji Kato, Hisato Kigasawa, Hisashi Sakamaki, Masahiro Tsuchida, Shunichi Kato, Takakaza Kawase, Hideki Muramatsu, Yasuo Morishima, Yoshihisa Kodera Tags: Clinical Research Source Type: journals

Polymorphism of Interleukin-23 Receptor Gene But Not of NOD2/CARD15 Is Associated with Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation in ChildrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The selection of a suitable donor is the most critical issue in preventing severe GVHD. Recent data suggest that the risk of GVHD does not only depend on human leukocyte antigens (HLA) but also on polymorphisms of genes that influence immune responses. We analyzed the 1142 G>A single-nucleotide polymorphism (SNP) in the interleukin-23 receptor gene (IL23R) and 3 SNPs in the NOD2/CARD15 gene in a cohort of 231 children who underwent allogeneic stem cell transplantation and/or their res...
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: Bernd Gruhn, Juliane Intek, Nadine Pfaffendorf, Roland Zell, Selim Corbacioglu, Felix Zintl, James F. Beck, Klaus-Michael Debatin, Daniel Steinbach Tags: Clinical Research Source Type: journals

A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of DeescalationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, we demonstrate the feasibility of reducing the dose of alemtuzumab as GVHD-prophylaxis to 10 mg absolute in combination with CsA only for UD transplantation in particular. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: Hartmut Bertz, Alexandros Spyridonidis, Ralph Wäsch, Carsten Grüllich, Mathias Egger, Jürgen Finke Tags: Clinical Research Source Type: journals

Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Success of hematopoietic cell transplantation (HCT) can vary by race, but the impact of socioeconomic status (SES) is not known. To evaluate the role of race and SES, we studied 6207 unrelated-donor myeloablative (MA) HCT recipients transplanted between 1995 and 2004 for acute or chronic leukemia or myelodysplastic syndrome (MDS). Patients were reported by transplant center to be White (n = 5253), African American (n = 368), Asian/Pacific-Islander (n = 141), or Hispanic (n = 445). Patient income was estimated from residential zip code at time of HCT. Cox regression analysis adjusting for other significant factors showed th...
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: K. Scott Baker, Stella M. Davies, Navneet S. Majhail, Anna Hassebroek, John P. Klein, Karen K. Ballen, Carolyn L. Bigelow, Haydar A. Frangoul, Cheryl L. Hardy, Christopher Bredeson, Jason Dehn, Debra Friedman, Theresa Hahn, Gregory Hale, Hillard M. Lazaru Tags: Clinical Research Source Type: journals

Infectious Complications after Unrelated Umbilical Cord Blood Transplantation in Adult Patients with Hematologic MalignanciesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, this data suggests that UCBT can be performed in adult patients with hematologic malignancies with an acceptable incidence of IRM provided a sufficient dose of nucleated cells is infused to the patient. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: Xavier Cahu, Fanny Rialland, Cyrille Touzeau, Patrice Chevallier, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Viviane Dubruille, Steven Le Gouill, Beatrice Mahe, Thomas Gastinne, Nicolas Blin, Beatrice Saulquin, Jean-Luc Harousseau, Philippe Moreau, Tags: Clinical Research Source Type: journals

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Graft-versus-host disease (GVHD) following bone marrow transplantation (BMT) is mediated by alloreactive donor T lymphocytes. Migration and activation of donor-derived T lymphocytes play critical roles in the development of GVHD. Leukocyte function–associated antigen-1 (LFA-1) regulates T cell adhesion and activation. We previously demonstrated that the I-domain, the ligand-binding site of LFA-1, changes from the low-affinity state to the high-affinity state on LFA-1 activation. Therapeutic antagonists, such as statins, inhibit LFA-1 activation and immune responses by modulating the affinity state of the LFA-1 I-domain. ...
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: Yang Wang, Dan Li, Dan Jones, Roland Bassett, George E. Sale, Jahan Khalili, Krishna V. Komanduri, Daniel R. Couriel, Richard E. Champlin, Jeffrey J. Molldrem, Qing Ma Tags: Biology Source Type: journals

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Anti-Tumor Necrosis Factor Alpha (TNF-α) therapy with infliximab has shown to be effective for patients with steroid-refractory acute graft-versus-host disease (aGVHD). An open-labeled, phase III trial was conducted to determine if the addition of infliximab to steroids could improve results for patients with newly diagnosed grade II-IV aGVHD. A total of 63 patients were randomized either to 2 mg/kg/day methylprednisolone (MP) or infliximab+ MP. Average age was 47 years (range: 20-70 years); 64% were male. Fifty-three percent and 51% of patients received a matched-sibling and/or bone marrow (BM) graft. Sixty-seven percent...
Source: Biology of Blood and Marrow Transplantation - September 11, 2009 Category: Hematology Authors: Daniel R. Couriel, Rima Saliba, Marcos de Lima, Sergio Giralt, Borje Andersson, Issa Khouri, Chitra Hosing, Cindy Ippoliti, Elizabeth J. Shpall, Richard Champlin, Amin Alousi Tags: Clinical Research Source Type: journals

Endovenous Administration of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells Prevents Renal Failure in Diabetic MiceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Twenty-five to 40% of diabetic patients develop diabetic nephropathy, a clinical syndrome that comprises renal failure and increased risk of cardiovascular disease. It represents the major cause of chronic kidney disease and is associated with premature morbimortality of diabetic patients. Multipotent mesenchymal stromal cells (MSC) contribute to the regeneration of several organs, including acutely injured kidney. We sought to evaluate if MSC protect kidney function and structure when endovenously administered to mice with severe diabetes. A month after nonimmunologic diabetes induction by streptozotocin injection, C57BL/...
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Authors: Fernando Ezquer, Marcelo Ezquer, Valeska Simon, Fabian Pardo, Alejandro Yañez, Daniel Carpio, Paulette Conget Tags: Biology Source Type: journals

Table of ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

Officers and Directors of ASBMTEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

MastheadEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Tags: Frontmatter Source Type: journals

ErratumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In “A Phase II Trial of Autologous Stem Cell Transplant followed by Mini-Allogeneic Stem Cell Transplant for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97” (Vesole et al., Biol Blood Marrow Transplant. 2009:15:83-91) an author was omitted. The additional author is Carol A. Huff, M.D., of Johns Hopkins University, Baltimore, Maryland. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Tags: Erratum Source Type: journals

2010 BMT Tandem Meetings Will Be Feb. 24–28 in OrlandoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The combined 2010 annual meetings of ASBMT and the Center for International Blood and Marrow Transplant Research (CIBMTR) will be Feb. 24-28 at the Rosen Shingle Creek Convention Center in Orlando, Fla. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Tags: ASBMT News Source Type: journals

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Marcie Tomblyn, University of Minnesota, Minneapolis, MN (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Authors: Marcie Tomblyn, Tom Chiller, Hermann Einsele, Ronald Gress, Kent Sepkowitz, Jan Storek, John R. Wingard, Jo-Anne H. Young, Michael A. Boeckh Tags: Guidelines Source Type: journals

Antibody Response to Polysaccharide Conjugate Vaccines after Nonmyeloablative Allogeneic Stem Cell TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, the reconstitution of humoral immunity after allo-RIST is determined by measuring the vaccination-induced antibody response against Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and tetanus toxoid (TT) 1 year posttransplantation. Patients who underwent allo-RIST were vaccinated according to a schedule starting at 12 months following transplantation with conjugated vaccines against S. pneumoniae, Hib, and TT. Of twenty-six patients both pre- and postvaccination sera were available. Patients were required to be off immunosuppression at the time of vaccination, and, therefore, 9 of the 26 patie...
Source: Biology of Blood and Marrow Transplantation - September 10, 2009 Category: Hematology Authors: Aafke Meerveld-Eggink, Ankie M.T. van der Velden, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Douwe H. Biesma, Ger T. Rijkers Tags: Clinical Research Source Type: journals

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Incorporation of the anti-CD20 monoclonal antibody rituximab into front-line regimens to treat diffuse large B cell lymphoma (DLBCL) has resulted in improved survival. Despite this progress, however, many patients develop refractory or recurrent DLBCL and then undergo autologous hematopoietic stem cell transplantation (AuHCT). It is unclear to what extent pre-transplant exposure to rituximab affects outcomes after AuHCT. Outcomes of 994 patients receiving AuHCT for DLBCL between 1996 and 2003 were analyzed according to whether rituximab was (n = 176; +R cohort) or was not (n = 818; −R cohort) administered with front-line...
Source: Biology of Blood and Marrow Transplantation - September 9, 2009 Category: Hematology Authors: Timothy S. Fenske, Parameswaran N. Hari, Jeanette Carreras, Mei-Jie Zhang, Rammurti T. Kamble, Brian J. Bolwell, Mitchell S. Cairo, Richard E. Champlin, Yi-Bin Chen, César O. Freytes, Robert Peter Gale, Gregory A. Hale, Osman Ilhan, H. Jean Khoury, John Tags: Clinical Research Source Type: journals

Donor KIR3DL1/3DS1 Gene and Recipient Bw4 KIR Ligand as Prognostic Markers for Outcome in Unrelated Hematopoietic Stem Cell TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Given their antileukemic activity, natural killer (NK) cells can alter the outcome of hematopoietic stem cell transplantation (HSCT). The physiologic functions of NK cells are regulated by the interaction of killer immunoglobulin-like receptors (KIR) with specific HLA class I ligands. In the literature, different models based on HLA class I and/or KIR donor (D)/recipient (R) gene disparities are considered as predictors of NK cell alloreactivity. In this retrospective and multicentric French study, we analyzed the clinical impact of the different NK-alloreactivity models in 264 patients who underwent T repleted unrelated H...
Source: Biology of Blood and Marrow Transplantation - September 9, 2009 Category: Hematology Authors: Katia Gagne, Marc Busson, Jean-Denis Bignon, Marie-Lorraine Balère-Appert, Pascale Loiseau, Anne Dormoy, Valérie Dubois, Pascale Perrier, Isabelle Jollet, Monique Bois, Dominique Masson, Agnès Moine, Léna Absi, Didier Blaise, Dominique Charron, Colett Tags: Clinical Research Source Type: journals

A “No-wash” Albumin-Dextran Dilution Strategy for Cord Blood Unit Thaw: High Rate of Engraftment and a Low Incidence of Serious Infusion ReactionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Preparation of cord blood (CB) units for infusion by albumin-dextran dilution without centrifugation may be advantageous for adult patients to minimize cell loss and, unlike a bedside thaw, is still conducted in the controlled laboratory environment. Therefore, we studied CB transplantation (CBT) using this technique in 54 consecutive CBT recipients >20 kg. Patients (median age=42 years [range: 7-66 years]; median weight=71 kg [range: 24-109]) were transplanted for high-risk hematologic malignancies with myeloablative (n=35) or nonmyeloablative (n=19) conditioning and 4-6/6 human leukocyte antigen (HLA)-matched double-unit...
Source: Biology of Blood and Marrow Transplantation - September 7, 2009 Category: Hematology Authors: Juliet N. Barker, Michelle Abboud, Robert D. Rice, Rebecca Hawke, Allison Schaible, Glenn Heller, Vincent La Russa, Andromachi Scaradavou Tags: Clinical Research Source Type: journals

Incidence of Viral and Fungal Infections following Busulfan-Based Reduced-Intensity versus Myeloablative Conditioning in Pediatric Allogeneic Stem Cell Transplantation RecipientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Reductions in the duration and nadir of neutropenia have translated into a significant decrease in bacteremia in adult recipients of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning (RIC) during the first 30 days after transplantation. It remains to be determined whether RIC allo-SCT also will result in a decrease in systemic viral infections (SVIs) and invasive fungal infections (IFIs), which are more dependent on alterations in cellular immunity. We compared the incidence of SVIs and IFIs in children receiving busulfan-based RIC allo-SCT and in children receiving myeloablative condition...
Source: Biology of Blood and Marrow Transplantation - September 7, 2009 Category: Hematology Authors: Prakash Satwani, Leah Baldinger, Jason Freedman, Judith S. Jacobson, Jon Guerra, Carmella van de Ven, Erin Morris, James Garvin, Diane George, M. Brigid Bradley, Monica Bhatia, Bradford Tallamy, Joseph Schwartz, Zhezhen Jin, Mitchell S. Cairo Tags: Clinical Research Source Type: journals

Successful Stem Cell Remobilization Using Plerixafor (Mozobil) Plus Granulocyte Colony-Stimulating Factor in Patients with Non-Hodgkin Lymphoma: Results from the Plerixafor NHL Phase 3 Study Rescue ProtocolEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In a phase 3 multicenter, randomized, double-blinded, placebo-controlled study of 298 patients with non-Hodgkin lymphoma (NHL), granulocyte colony-stimulating factor (G-CSF) plus plerixafor increased the proportion of patients who mobilized ≥5 × 106 CD34+ hematopoietic stem cells (HSCs)/kg compared with placebo plus G-CSF (P < .001). Patients in either study arm who failed mobilization (< 0.8 × 106 CD34+ cells/kg in 2 collections or (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 7, 2009 Category: Hematology Authors: Ivana N. Micallef, Patrick J. Stiff, John F. DiPersio, Richard T. Maziarz, John M. McCarty, Gary Bridger, Gary Calandra Tags: Clinical Research Source Type: journals

Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pertussis is a highly contagious respiratory infection characterized by prolonged cough and inspiratory whoop. Despite widespread vaccination of children aged2-fold response to PT following vaccination with Tdap. These data suggest that autologous transplantation recipients are highly susceptible to pertussis and that immunization with 2.5μg of PT induces an inadequate response. Prospective trials evaluating BOOSTRIX, containing 8μg/dose of PT (approved for adults in December 2008) are warranted in this vulnerable population undergoing transplantation. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 7, 2009 Category: Hematology Authors: Trudy N. Small, Andrew D. Zelenetz, Ariela Noy, R. David Rice, Tanya M. Trippett, Lauren Abrey, Carol S. Portlock, Emily J. McCullagh, Jill M. Vanak, Ann Marie Mulligan, Craig H. Moskowitz Tags: Clinical Research Source Type: journals

Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in Perceived Importance Over TimeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hematopoietic stem-cell transplantation (HSCT) is associated with high rates of gonadal failure, which is distressing for younger patients desiring to start a family. The perceived importance and optimal timing of discussing fertility- and menopause-related information with women undergoing aggressive treatment such as HSCT is not well defined. Questionnaires were sent to 532 patients who underwent HSCT between January 1987 and September 2004 at the ages of 16 to 50 years. The questionnaire assessed demographic data, the need for fertility- and menopause-related information at various times during treatment, and standardiz...
Source: Biology of Blood and Marrow Transplantation - September 6, 2009 Category: Hematology Authors: Kazutaka Nakayama, Ping Liu, Michelle Detry, Leslie R. Schover, Andrea Milbourne, Joyce Neumann, Gabriela Rondon, Belinda Thewes, Richard E. Champlin, Naoto T. Ueno Tags: Clinical Research Source Type: journals

Dichotomous Role of Interferon-γ in Allogeneic Bone Marrow TransplantEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Interferon (IFN)-γ is a pleiotropic cytokine with a central role in innate and adaptive immunity. As a potent pro-inflammatory and antitumor cytokine, IFN-γ is conventionally thought to be responsible for driving cellular immune response. On the other hand, accumulating evidence suggests that IFN-γ also has immunosuppressive activity. An important role for IFN-γ in inhibiting graft-versus-host disease (GVHD) has been demonstrated in murine models, despite IFN-γ being one of the key factors amplifying T cell activation during the process of acute GVHD (aGVHD), the major complication and cause of post-transplant mortali...
Source: Biology of Blood and Marrow Transplantation - September 6, 2009 Category: Hematology Authors: Ying Lu, Edmund K. Waller Tags: Review Source Type: journals

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell MobilizationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We evaluated stem cell mobilization in 195 consecutive sibling donors who underwent a uniform mobilization regimen of granulocyte colony-stimulating factor (G-CSF) at 10μg/kg/day divided into twice daily dosing. On day 5, peripheral blood (PB) CD34 cells/μL were measured immediately prior to peripheral blood stem cell (PBSC) apheresis. Failed mobilization was defined as (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 3, 2009 Category: Hematology Authors: Elie Richa, Mona Papari, JoAnn Allen, Guadalupe Martinez, Amittha Wickrema, John Anastasi, Koen Van Besien, Andrew Artz Tags: Clinical Research Source Type: journals

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Acute lymphoblastic leukemia (ALL) with high-risk features has a poor prognosis in adults despite aggressive chemotherapy. Reduced-intensity conditioning (RIC) is a lower toxicity alternative for high-risk patients requiring hematopoietic cell transplantation (HCT); however, it has not been widely used for ALL. We conducted a retrospective study of 24 high-risk adult ALL patients who received an RIC regimen of fludarabine (Flu)/melphalan (Mel) prior to allogeneic peripheral blood stem cell transplantation (PBSCT) between 6/14/02 and 6/15/07 at the City of Hope. Indications for the RIC regimen were: (1) aged 50 years or old...
Source: Biology of Blood and Marrow Transplantation - September 2, 2009 Category: Hematology Authors: Anthony S. Stein, Joycelynne M. Palmer, Margaret R. O'Donnell, Neil M. Kogut, Ricardo T. Spielberger, Marilyn L. Slovak, Ni-Chun Tsai, David Senitzer, David S. Snyder, Sandra H. Thomas, Stephen J. Forman Tags: Clinical Research Source Type: journals

Impact of Declining Fertility Rates in Canada on Donor Options in Blood and Marrow TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
An HLA-matched sibling remains the optimal donor for most patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Marked declines in total fertility rates in Canada over the past 50 years will lead to increasing numbers of patients without sibling donors well into the future. We retrieved transplantation data from a Canadian center and the Canadian Blood and Marrow Transplant Group and total fertility data from the United Nations Department of Economic and Social Affairs. The mean age of adults with acute myelogenous leukemia (AML), who underwent transplantation at The Ottawa Hospital between 1995 an...
Source: Biology of Blood and Marrow Transplantation - September 2, 2009 Category: Hematology Authors: David S. Allan, Sarah Takach, Susan Smith, Mindy Goldman Tags: Brief Articles Source Type: journals

Defining the Intensity of Conditioning Regimens: Working DefinitionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This report also assigns commonly used regimens to one of these categories, based upon the agents, dose, or combinations. Standardized classification of conditioning regimen intensities will allow comparison across studies and interpretation of study results. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 2, 2009 Category: Hematology Authors: Andrea Bacigalupo, Karen Ballen, Doug Rizzo, Sergio Giralt, Hillard Lazarus, Vincent Ho, Jane Apperley, Shimon Slavin, Marcelo Pasquini, Brenda M. Sandmaier, John Barrett, Didier Blaise, Robert Lowski, Mary Horowitz Tags: Brief Articles Source Type: journals

Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide–Based RegimenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In patients with relapsed acute promyelocytic leukemia (APL), the best consolidation regimen following induction of remission with arsenic trioxide (ATO) remains to be defined. Since January 2000, 37 patients with relapsed APL were treated at our center. The median age was 34 years (range, 6-57 years), and there were 20 males (54.1%). The median duration of first remission was 20.3 months (range, 2.9-81.2 months). Relapse was treated with single-agent ATO in 22 patients (59.5%), ATO+ATRA in 5 patients (13.5%), and ATO+ATRA + anthracycline in 10 patients (27%). Thirty-three patients (89%) achieved molecular remission after ...
Source: Biology of Blood and Marrow Transplantation - September 1, 2009 Category: Hematology Authors: Rajasekar Thirugnanam, Biju George, Ezhil Chendamarai, Kavitha M. Lakshmi, Poonkuzhali Balasubramanian, Auro Viswabandya, Alok Srivastava, Mammen Chandy, Vikram Mathews Tags: Brief Articles Source Type: journals

Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution ExperienceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study is a retrospective analysis of 78 consecutive patients with NHL who underwent ASCT with Bu/Cy at Massachusetts General Hospital Cancer Center. Data were collected through review of electronic medical records. A total of 78 patients with NHL underwent ASCT with Bu/Cy preparative therapy between 1996 and 2006. Median follow-up for survivors was 5.0 years (range, 6 months to 12 years). Significant transplantation-associated complications included 9 documented bacterial infections, 4 cases of engraftment syndrome, 3 cases of hepatic veno-occlusive disease (VOD), 6 cases of cardiac complications, and 2 cases of pulmo...
Source: Biology of Blood and Marrow Transplantation - September 1, 2009 Category: Hematology Authors: Matthew Ulrickson, Julie Aldridge, Haesook T. Kim, Ephraim P. Hochberg, Peter Hammerman, Christine Dube, Eyal Attar, Karen K. Ballen, Bimalangshu R. Dey, Steven L. McAfee, Thomas R. Spitzer, Yi-Bin Chen Tags: Clinical Research Source Type: journals

Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, our study showed that NC are observed after allo-RIC and have diverse features. NC affecting the CNS have earlier onset and worse outcome than those involving the PNS. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 1, 2009 Category: Hematology Authors: Pere Barba, Jose Luis Piñana, David Valcárcel, Luis Querol, Rodrigo Martino, Anna Sureda, Javier Briones, Julio Delgado, Salut Brunet, Jorge Sierra Tags: Clinical Research Source Type: journals

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the recommended therapy for patients with relapsed acute myelogenous leukemia (AML), despite little evidence showing a survival benefit in patients who undergo HSCT versus chemotherapy alone. Because a prospective randomized trial addressing this issue is unlikely, we retrospectively reviewed all patients receiving initial salvage therapy for AML at M.D. Anderson Cancer Center between 1995 and 2004, focusing on patients undergoing HSCT or chemotherapy without HSCT as second salvage after first salvage failed to produce complete remission (CR) (group A) and patien...
Source: Biology of Blood and Marrow Transplantation - September 1, 2009 Category: Hematology Authors: Paul M. Armistead, Marcos de Lima, Sherry Pierce, Wei Qiao, Xuemei Wang, Peter F. Thall, Sergio Giralt, Farhad Ravandi, Hagop Kantarjian, Richard Champlin, Elihu Estey Tags: Clinical Research Source Type: journals

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic MalignanciesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We sought to reduce the risk of infectious complications and nonrelapse mortality (NRM) associated with the use of antithymocyte globulin (ATG) without compromising control of acute graft-versus-host disease (aGVHD) in patients undergoing reduced-intensity conditioning (RIC) transplantation. As part of an ongoing quality improvement effort, we lowered the dose of rabbit ATG from 7.5 mg/kg of ATG (R-ATG) (n = 39) to 6.0 mg/kg of ATG (r-ATG) (n = 33) in association with fludarabine (Flu) and busulfan (BU) RIC transplantation and then monitored patients for adverse events, relapse, and survival. Of the 72 mostly high risk (82...
Source: Biology of Blood and Marrow Transplantation - September 1, 2009 Category: Hematology Authors: Mehdi Hamadani, William Blum, Gary Phillips, Patrick Elder, Leslie Andritsos, Craig Hofmeister, Lynn O'Donnell, Rebecca Klisovic, Sam Penza, Ramiro Garzon, David Krugh, Thomas Lin, Thomas Bechtel, Don M. Benson, John C. Byrd, Guido Marcucci, Steven M. Dev Tags: Clinical Research Source Type: journals

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Peripheral blood stem cells (PBSCs) and bone marrow (BM) hematopoietic stem cells represent therapeutic alternatives in allogeneic hematopoietic cell transplantation. Randomized controlled trials and an individual patient data meta-analysis (IPDMA) have demonstrated a decreased risk of disease relapse and an increased risk of acute and chronic graft-versus-host disease (aGVHD, cGVHD) in patients receiving PBSCs compared with those receiving BM stem cells. Decision modeling provides quantitative integration of the risks and benefits associated with these alternative treatments, incorporates survival discounts for lower qual...
Source: Biology of Blood and Marrow Transplantation - September 1, 2009 Category: Hematology Authors: Joseph Pidala, Claudio Anasetti, Mohamed A. Kharfan-Dabaja, Corey Cutler, Andy Sheldon, Benjamin Djulbegovic Tags: Clinical Research Source Type: journals